Search

Displaying results 2391 - 2400 of 10000 in total
  1. Drug

    RP-67580

    go.drugbank.com/drugs/DB16742
    Experimental

    Categories: Heterocyclic Compounds, 2-Ring, Neurokinin-1 Receptor Antagonists
  2. Drug

    Cytochalasin B

    go.drugbank.com/drugs/DB16766
    Experimental

    Categories: Heterocyclic Compounds, 2-RingSynonyms: Cytochalasin B, Cytochalasin-B
  3. Drug

    Tyrphostin B56

    go.drugbank.com/drugs/DB16775
    Experimental

    Categories: Heterocyclic Compounds, 2-Ring
  4. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. … Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent.

    Categories: Compounds used in a research, industrial, or household settingProducts: 1 Pluvicto
  5. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706] … Adlinacogene civaparvovec is an investigational _in vivo_ genome editing therapeutic product.

  6. Drug

    Lixmabegagene relduparvovec

    go.drugbank.com/drugs/DB16816
    Investigational

    Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). … It is under development for the treatment of GM1 gangliosidosis.[L45929]

  7. Drug

    AZD-5069

    go.drugbank.com/drugs/DB16822
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741]

    Categories: MATE 2 Inhibitors, P-glycoprotein inhibitorsSynonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE, (7S,13R)-11-Fluoro-7,13-Dimethyl-6,7,13,14-Tetrahydro-1,15-Ethenopyrazolo[4,3-F][1,4,8,10]Benzoxatriazacyclotridecin-4(5H)-One
  9. Drug

    AZD-7648

    go.drugbank.com/drugs/DB16834
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  10. Drug

    Pidnarulex

    go.drugbank.com/drugs/DB16846
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring